Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results

被引：0
|
作者：
Bardia, A.
Diamond, J. R.
Mayer, I. A.
Isakoff, S. J.
Abramson, V.
Starodub, A. N.
O'Shaughnessy, J.
Kalinsky, K.
Moroose, R.
Shah, N.
Juric, D.
Shapiro, G. I.
Guarino, M.
Ocean, A. J.
Messersmith, W. A.
Berlin, J. D.
Wegener, W. A.
Sharkey, R. M.
Goldenberg, D. M.
Vahdat, L. T.
机构：
[1] Massachusetts Gen Hosp, Harvard Med Sch, Ctr Canc, Boston, MA 02114 USA
[2] Univ Colorado, Ctr Canc, Aurora, CO USA
[3] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] Indiana Univ, Hlth Ctr Canc Care, Goshen, IN USA
[5] Texas Oncol Sammons Canc Ctr, Dallas, TX USA
[6] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA
[7] Univ Florida, Hlth Canc Ctr, Orlando, FL USA
[8] Dana Farber Canc Inst, Harvard Med Sch, Boston, MA 02115 USA
[9] Helen F Graham Canc Ctr, Newark, DE USA
[10] Weill Cornell Med, New York, NY USA
[11] Immunomed Inc, Morris Plains, NJ USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P4-22-15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-22-15
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase III, randomized trial of sacituzumab govitecan (IMMU-132) vs treatment of physician choice (TPC) for metastatic triple-negative breast cancer (mTNBC)
    Bardia, Aditya
    Rugo, Hope S.
    Horne, Heather
    Wegener, William A.
    Goldenberg, David M.
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2018, 78 (04)
  • [22] Pharmacokinetics of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, in patients with diverse advanced solid tumors
    Sharkey, Robert M.
    Ocean, Allyson J.
    Starodub, Alexander N.
    Bardia, Aditya
    Guarino, Michael
    Messersmith, Wells A.
    Berlin, Jordan D.
    Picozzi, Vincent J.
    Moroose, Rebecca
    Wegener, William A.
    Maliakal, Pius
    Govindan, Serengulam V.
    Goldenberg, David M.
    CANCER RESEARCH, 2017, 77
  • [23] Advanced solid cancer therapy with a novel antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): key preclinical and clinical results
    Starodub, Alexander N.
    Ocean, Allyson J.
    Bardia, Aditya
    Guarino, Michael J.
    Messersmith, Wells
    Berlin, Jordan
    Picozzi, Vincent J.
    Thomas, Sajeve S.
    Masters, Gregory
    Vandat, Linda T.
    Mayer, Ingrid A.
    Moroose, Rebecca
    Diamond, Jennifer S.
    Tagawa, Scott T.
    Shah, Manish A.
    Wilhelm, Francois
    Wegener, William A.
    Maliakal, Pius
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER RESEARCH, 2015, 75
  • [24] Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132) in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).
    Starodub, Alexander
    Camidge, D. Ross
    Scheff, Ronald J.
    Thomas, Sajeve Samuel
    Guarino, Michael J.
    Masters, Gregory A.
    Kalinsky, Kevin
    Gandhi, Leena
    Bardia, Aditya
    Messersmith, Wells A.
    Ocean, Allyson J.
    Maliakal, Pius P.
    Sharkey, Robert M.
    Wilhelm, Francois
    Goldenberg, David M.
    Heist, Rebecca Suk
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC
    Bardia, A.
    Diamond, J. R.
    Mayer, I. A.
    Starodub, A. N.
    Moroose, R. L.
    Isakoff, S. J.
    Ocean, A. J.
    Guarino, M. J.
    Berlin, J. D.
    Messersmith, W. A.
    Thomas, S. S.
    O'Shaughnessy, J. A.
    Kalinsky, K.
    Maurer, M.
    Chang, J. C.
    Forero, A.
    Traina, T.
    Gucalp, A.
    Wilhelm, F.
    Wegener, W. A.
    Maliakal, P.
    Sharkey, R. M.
    Goldenberg, D. M.
    Vahdat, L. T.
    CANCER RESEARCH, 2016, 76
  • [26] Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2-metastatic breast cancer (mBC)
    Bardia, Aditya
    Diamond, Jennifer Robinson
    Vahdat, Linda T.
    Tolaney, Sara M.
    O'Shaughnessy, Joyce
    Moroose, Rebecca L.
    Mayer, Ingrid A.
    Abramson, Vandana Gupta
    Juric, Dejan
    Sharkey, Robert M.
    Washkowitz, Sarah A.
    Wegener, William A.
    Goldenberg, David M.
    Kalinsky, Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552)
    Bardia, Aditya
    Starodub, Alexander
    Moroose, Rebecca L.
    Mayer, Ingrid A.
    Diamond, Jennifer R.
    Chuang, Ellen
    Govindan, Serengulam V.
    Sharkey, Robert M.
    Maliakal, Pius
    Wegener, William A.
    Hamburger, Steven A.
    Ocean, Allyson J.
    Goldenberg, David M.
    Vahdat, Linda T.
    CANCER RESEARCH, 2015, 75
  • [28] Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors
    Fenn, K. M.
    Kalinsky, K.
    DRUGS OF TODAY, 2019, 55 (09) : 575 - 585
  • [29] Synthetic lethality in TNBC mediated by an anti-Trop-2 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), when combined with paclitaxel or the PARP inhibitor, olaparib
    Goldenberg, D. M.
    Cardillo, T. M.
    Govindan, S. V.
    Zalath, M.
    Arrojo, R.
    Sharkey, R. M.
    CANCER RESEARCH, 2016, 76
  • [30] IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Trop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.
    Starodub, Alexander
    Ocean, Allyson J.
    Guarino, Michael J.
    Picozzi, Vincent J.
    Thomas, Salim Samuel
    Messersmith, Wells A.
    Shah, Manlsh A.
    Vandat, Linda T.
    Chuang, Ellen
    Lin, Bruce S.
    Govindan, Serengulam V.
    Maliakal, Pius P.
    Wegener, William A.
    Hamburger, Steven A.
    Sharkey, Robert M.
    Goldenberg, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345